ATE447944T1 - Verwendung von formoterol in der prophylaktischen und/oder therapeutischen behandlung von muskelschwund und/oder kachexie-syndrom im zusammenhang mit katabolischen zuständen bei bestimmten krankheiten, wie z.b. krebs, aids, infektionen, diabetes und andere - Google Patents

Verwendung von formoterol in der prophylaktischen und/oder therapeutischen behandlung von muskelschwund und/oder kachexie-syndrom im zusammenhang mit katabolischen zuständen bei bestimmten krankheiten, wie z.b. krebs, aids, infektionen, diabetes und andere

Info

Publication number
ATE447944T1
ATE447944T1 AT05763090T AT05763090T ATE447944T1 AT E447944 T1 ATE447944 T1 AT E447944T1 AT 05763090 T AT05763090 T AT 05763090T AT 05763090 T AT05763090 T AT 05763090T AT E447944 T1 ATE447944 T1 AT E447944T1
Authority
AT
Austria
Prior art keywords
formoterol
prophylactic
diabetes
aids
cancer
Prior art date
Application number
AT05763090T
Other languages
English (en)
Inventor
Huguet Jose Maria Argiles
Soriano Francisco Javier Lapez
Rius Silvia Busquets
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Application granted granted Critical
Publication of ATE447944T1 publication Critical patent/ATE447944T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AT05763090T 2004-06-29 2005-06-28 Verwendung von formoterol in der prophylaktischen und/oder therapeutischen behandlung von muskelschwund und/oder kachexie-syndrom im zusammenhang mit katabolischen zuständen bei bestimmten krankheiten, wie z.b. krebs, aids, infektionen, diabetes und andere ATE447944T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200401941A ES2245612B1 (es) 2004-06-29 2004-06-29 Nuevo uso terapeutico del formoterol.
PCT/ES2005/000365 WO2006003222A1 (es) 2004-06-29 2005-06-28 Uso del formoterol en el tratamiento profiláctico y/o terapéutico del desgaste muscular y/o síndrome caquéctico, asociados a estados catabólicos de ciertas enfermedades como cáncer, sida, infecciones, diabetes y otras

Publications (1)

Publication Number Publication Date
ATE447944T1 true ATE447944T1 (de) 2009-11-15

Family

ID=35614437

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05763090T ATE447944T1 (de) 2004-06-29 2005-06-28 Verwendung von formoterol in der prophylaktischen und/oder therapeutischen behandlung von muskelschwund und/oder kachexie-syndrom im zusammenhang mit katabolischen zuständen bei bestimmten krankheiten, wie z.b. krebs, aids, infektionen, diabetes und andere

Country Status (9)

Country Link
EP (1) EP1818052B1 (de)
AT (1) ATE447944T1 (de)
CY (1) CY1109771T1 (de)
DE (1) DE602005017659D1 (de)
DK (1) DK1818052T3 (de)
ES (2) ES2245612B1 (de)
PL (1) PL1818052T3 (de)
PT (1) PT1818052E (de)
WO (1) WO2006003222A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0625270D0 (en) * 2006-12-19 2007-01-31 Univ Leicester Angiogenesis
KR101546977B1 (ko) * 2007-04-24 2015-08-24 아카시아 파마 리미티드 근육 손실의 치료에서의 약물 조합 및 그것의 용도
CN117562998A (zh) * 2023-02-02 2024-02-20 上海市第十人民医院 长效β2AR激动剂在制备治疗癌症药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903995D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New combination
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
WO2002066021A2 (de) * 2001-02-22 2002-08-29 Universitätsklinikum Charite Medizinische Fakultät Der Humboldt-Universität Zu Berlin Inhibitoren der protein kinase d und der protein kinase 2 als mittel zur hemmung von tumorzellen und zur stimulierung der angiogehese

Also Published As

Publication number Publication date
EP1818052B1 (de) 2009-11-11
ES2245612A1 (es) 2006-01-01
WO2006003222A9 (es) 2009-01-15
DE602005017659D1 (de) 2009-12-24
ES2245612B1 (es) 2007-08-16
PT1818052E (pt) 2010-02-15
DK1818052T3 (da) 2010-03-29
EP1818052A1 (de) 2007-08-15
CY1109771T1 (el) 2014-09-10
ES2336229T3 (es) 2010-04-09
PL1818052T3 (pl) 2010-04-30
WO2006003222A1 (es) 2006-01-12

Similar Documents

Publication Publication Date Title
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
DE60336664D1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
EA200501095A1 (ru) Фенилацетамиды и их применение в качестве модуляторов глюкокиназы
CL2003002353A1 (es) Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
ATE531382T1 (de) Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen
EA200601747A1 (ru) Три(цикло)замещённые амидные соединения
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
DE60335647D1 (de) Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden
DE602005024571D1 (de) Opioide zur behandlung von ruhelosigkeit in den unteren gliedmassen
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
ECSP055844A (es) Nuevos compuestos triciclicos
CY1109771T1 (el) Η χρηση της φορμοτερολης στην προφυλακτικη και/ή θεραπευτικη αντιμετωπιση της μυικης απωλειας και/ή του καχεκτικου συνδρομου τα οποια συνδεονται με τις καταβολικες συνθηκες ορισμενων παθησεων. οπως ο καρκινος, to aids, οι μολυνσεις, ο διαβητης και αλλες
ATE380554T1 (de) Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie
DE60208701D1 (de) Verwendung von cetrorelix zur behandlung vom jakob-creutzfeldt-syndrom
CO2023007851A2 (es) Proteínas de unión a il-7 y su uso en tratamientos médicos
DK1416937T3 (da) Profylaktisk og terapeutisk anvendelse af hydroxysteroider
BR0313665A (pt) Utilização de bupropion para o tratamento da sìndrome das pernas inquietas
DE50203154D1 (de) Benzimidazolderivate zur behandlung von mit mikroglia-aktivierung assoziierten erkrankungen wie inflammatorische, allergische, infektiöse oder autoimmune erkrankungen
WO2007117272A3 (en) Methods for treatment of hemorrhagic shock and related disorders
ATE426410T1 (de) Behandlung der oralen und darm mukositis durch verabreichung von menschlichem il-18
DE60304678D1 (de) Idraparinux (sanorg 34006) zur behandlung und sekundärprophylaxe von thromboembolien bei patienten mit tiefer venenthrombose
HUP0402645A2 (hu) Egy glitazont és egy 4-oxobutánsavat tartalmazó gyógyászati készítmény és ennek alkalmazása cukorbetegség kezelésére
RU2004128515A (ru) Способ восстановления кожного покрова при комбинированных радиационно-ожоговых поражениях
RU2004123072A (ru) Способ лечения больных остеоартрозом

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1818052

Country of ref document: EP